Fpckorea Policy Forum With Dapa

[Special Live] FPCKorea Policy Forum with DAPA (방위사업청장 초청 외신기자 정책토론회)

[Special Live] FPCKorea Policy Forum on COVID-19 with MOHW and KDCA (코로나19 보건복지부-질병관리청 외신 정책토론회)

Korea Policy Forum with Prime Minister Nakyon Lee: Denuclearization & Peace on the Korean Peninsula

GW Institute for Korean Studies

KOFIH 제5회 Global Health Forum - 포스트 코로나, 탄자니아의 보건의료체계의 변화와 과제

KOFIH-Tube[코피튜브]

DAPA in CKD | RCT | Journal Club

Health is an Attitude | Dr Shoukat Memon

DAPA-CKD: Does confirmed renoprotection make the case for first-line SGLT2 inhibition? | Luigi Gnudi

Medicine Matters diabetes

HFA 2020: Dapagliflozin and diuretic use in patients with HFrEF in DAPA-HF — Dr Alice M Jackson

Radcliffe Cardiology

Early Detection Policy Forum organised by EUDF, IDF Europe, PDGN, FEDE, Sanofi

European Diabetes Forum

What is Dapagliflozin (Dapa)? | Usage and Prescription | Healthy Wrinkles | Dapagliflozin - Part 2

Healthy Wrinkles

A Comparison Of Sglt2 Drugs: Empagliflozin Vs Dapagliflozin

Dr. Ford Brewer

Understanding Diabetes and Kidney Health with Dapa | Healthy Wrinkles | Dapagliflozin - Part 1

Healthy Wrinkles

HF 2022: DELIVER Extends Benefits of Dapagliflozin to the Full Spectrum of Pts with HF

Radcliffe Cardiology

DAPA-CKD: Renal benefits of SGLT2 inhibition in people with and without diabetes | Hiddo Heerspink

Medicine Matters diabetes

Dr. Scott Solomon: Dapagliflozin Benefits Patients With Heart Failure and Kidney Disease

ESC 2019: DAPA-HF - A Perspective - Prof Giuseppe Rosano

Radcliffe Cardiology

Cardiovascular and renal outcomes with dapagliflozin in people with chronic kidney disease

Dapagliflozin clinically and cost effective in patients with chronic kidney disease DAPA CKD trial

Medical Dialogues

ESC TV at ESC Congress 2020 - DAPA-CKD (Discussant)

European Society of Cardiology

ACC 23: Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF

Radcliffe Cardiology

Dr. McMurray discusses the DAPA-HF trial of dapagliflozin in systolic heart failure